Harvard Bioscience (HBIO) Income from Discontinued Operations (2017 - 2018)
Harvard Bioscience's (HBIO) quarterly Income from Discontinued Operations came in at 442000.0 in Q4 2018, up 162.52% year-on-year from 168369.61 in Q4 2017, and up 4520.0% on a QoQ basis from 10000.0 in Q2 2018.
Harvard Bioscience (HBIO) Income from Discontinued Operations (2017 - 2018) Analysis & Trends
Harvard Bioscience (HBIO) has 2 years of Income from Discontinued Operations data on file, last reported at 442000.0 in Q4 2018.
- On a quarterly basis, Income from Discontinued Operations rose 162.52% year-over-year to 442000.0 in Q4 2018; TTM through Sep 2019 was 442000.0, a 127.8% increase from a year earlier, with the FY2018 full-year figure at 441000.0, up 28.53% from the prior year.
- Income from Discontinued Operations for Q4 2018 stood at 442000.0, up from 10000.0 in the prior quarter.
- Over the last five years, Income from Discontinued Operations for HBIO reached as high as 442000.0 in Q4 2018 and fell as low as 873000.0 in Q1 2018.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Discontinued) (Qtr) |
|---|---|---|---|---|---|
| 1 | Intuitive Surgical | 126.59 Bn | 121.37 Bn | 1.96 Bn | - |
| 2 | Becton Dickinson | 44.89 Bn | 44.07 Bn | 2.15 Bn | - |
| 3 | Alcon | 32.93 Bn | 31.27 Bn | 1.53 Bn | - |
| 4 | Medline | 32.81 Bn | 30.58 Bn | 1.84 Bn | - |
| 5 | Resmed | 29.39 Bn | 27.73 Bn | 890.98 Mn | - |
| 6 | West Pharmaceutical Services | 23.40 Bn | 22.97 Bn | 329.20 Mn | - |
| 7 | Solventum | 14.07 Bn | 13.51 Bn | 1.10 Bn | - |
| 8 | Cooper Companies | 13.78 Bn | 13.64 Bn | 735.40 Mn | - |
| 9 | Align Technology | 12.04 Bn | 10.98 Bn | 736.59 Mn | - |
| 10 | Harvard Bioscience | 27.35 Mn | 20.25 Mn | 12.24 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | 442,000.00 |
| Jun 30, 2018 | -10,000.00 |
| Mar 31, 2018 | -873,000.00 |
| Dec 31, 2017 | -707,000.00 |
| Sep 30, 2017 | 26,000.00 |
| Jun 30, 2017 | 34,000.00 |
| Mar 31, 2017 | 30,000.00 |